A route is not just a different way of delivering the same guaranteed result. It can change exposure, formulation requirements and the questions that need to be answered about safety. Personal reports of a stronger feeling do not establish which route is clinically preferable.
The primary Semax route-comparison experiment studied learning and pain-related outcomes in rats after intranasal or intraperitoneal administration. Intraperitoneal administration is not the same as a human subcutaneous route discussed online. The experiment also found that the pattern depended on the endpoint, which makes a single ranking of “better absorption” especially misleading.
A rat radiolabel study investigated distribution and breakdown after nasal administration. It distinguished labeled material associated with intact peptide from metabolites. Radioactivity detected in tissue is therefore not automatically a measurement of intact, active Semax throughout the body, and the rat findings cannot be relabeled as established human bioavailability.
Three questions need separate evidence: how much of a defined substance reaches a location, what biological effect it produces and whether the resulting clinical outcome is worth the risk. An answer to one does not settle the other two. Feeling an effect earlier would not, by itself, prove greater delivery to the intended target or improved safety.
The finished product matters as well. A preparation intended for one research setting cannot be assumed suitable for another route. The identity, formulation, manufacturing controls and relevant testing all remain part of the assessment. A percentage or concentration on a label does not resolve those questions.
A clinician or pharmacist reviewing route-related claims would need evidence for the exact intervention and intended use. No preparation instructions, administration technique or conversion between routes can be derived from the studies summarized here. Such a conversion would require more than an animal comparison and a collection of anecdotes.
This appraisal uses primary abstracts rather than complete pharmacokinetic datasets. The supported conclusion is that route-dependent effects have been investigated experimentally. A claim that a particular human route is superior, interchangeable or safe remains a separate clinical claim that these animal studies do not establish.